US Interchangeability ‘Irrelevant’ And ‘Makes No Sense’ Says Sandoz

At the recent Morgan Stanley Healthcare Conference in New York, Sandoz leaders set out their views on the significance of – and the FDA’s initial implementation of – the US biosimilar interchangeability designation.